Ambulatory Care Self-Assessment Program (ACSAP) Book 1: Endocrinology Care (Cert # L249108)

The target audience Ambulatory Care Self-Assessment Program (ACSAP) Book 1: Endocrinology Care is board-certified and advanced level ambulatory care clinical pharmacists.

Board certified pharmacists are eligible to receive up to 16.5 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.  

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

ACCP and ASHP are approved by BPS as a provider for the recertification of BCACP.

Endocrinology Care I
ACPE #: 0217-9999-24-027-H01-P
Chapter: Diabetes Drugs Improving Cardiorenal and Weight Management Outcomes

• Distinguish the differences between the drug therapy recommendations of several of the latest and leading diabetes guidelines regarding cardiorenal protection and weight management.
• Assess the differences in incretin-based and sodium-glucose cotransporter 2 therapies related to cardiorenal protection and weight management.
• Assess the differences in other medication therapies for diabetes related to cardiorenal protection and weight management.
• Devise a case-based therapeutic plan that considers drug therapy selection for a patient with diabetes related to cardiorenal protection and weight management. 

Chapter: Case Series: Acute Diabetes Management in Type 2 Diabetes

• Distinguish the signs and symptoms of hypoglycemia and hyperglycemia.
• Detect medications with a high risk of hypoglycemia or hyperglycemia.
• Evaluate the new glucagon therapies and their administration techniques.
• Design treatment plans for managing hypoglycemia and hyperglycemia. 

Endocrinology Care II
ACPE #: 0217-9999-24-028-H01-P
Chapter: Diabetes Technology

• Distinguish among the various diabetes technology options.
• Evaluate available evidence regarding the use of continuous glucose monitors and connected pens in patients with diabetes.
• Design a plan to educate and train patients with diabetes to ensure optimal diabetes technology use.
• Develop a therapy plan for patients with diabetes that incorporates diabetes technology in conjunction with standard of care. 

Chapter: Diabetes in Pregnancy

• Analyze the potential maternal and fetal complications associated with uncontrolled diabetes during pregnancy.
• Assess the various screening approaches used to diagnose gestational diabetes during pregnancy.
• Design a complete treatment plan for a patient with diabetes during pregnancy, including monitoring recommendations and nonpharmacologic and pharmacologic therapy.
• Evaluate the place in therapy for oral hypoglycemic regimens in the management of diabetes during pregnancy.
• Develop an intrapartum and postpartum treatment plan for a patient with diabetes during pregnancy. 

Endocrinology Care III
ACPE #: 0217-9999-24-029-H01-P

Chapter: Osteoporosis

• Evaluate risk factors and screening criteria for osteoporosis and determine appropriate preventive strategies.
• Distinguish differences between treatment approaches according to recent guideline updates.
• Develop an initial osteoporosis treatment regimen on the basis of patient-specific factors and evaluate treatment on the basis of changing clinical picture.
• Design a monitoring plan for a patient with osteoporosis, including adjustments on the basis of suboptimal response or different clinical scenarios. 

Chapter: Case Series: Thyroid Disorders

• Assess the benefits and limitations of different medication classes for the treatment of patients with hypothyroidism, patients with hyperthyroidism, pregnant patients with thyroid disorders, and patients with subclinical thyroid disorders.
• Design a drug therapy plan for patients with hypothyroidism, patients with hyperthyroidism, pregnant patients with thyroid disorders, and patients with subclinical thyroid disorders.
• Justify drug therapy selection for patients with hypothyroidism, patients with hyperthyroidism, pregnant patients with thyroid disorders, and patients with subclinical thyroid disorders. 

Endocrinology Care IV
ACPE #: 0217-9999-24-030-H01-P
Chapter: Gender-Affirming Care

• Discover opportunities for pharmacists to create safe and affirming environments of care for transgender and gender-diverse (TGD) individuals.
• Develop a comprehensive plan for a patient receiving masculinizing or feminizing hormone therapy.
• Develop a patient-specific plan to address risks and potential consequences associated with gender-affirming hormone therapy (e.g., impact on fertility, bone health, cardiovascular health).
• Evaluate gender-affirming care interventions for TGD youth for safety, efficacy, and appropriateness.
• Devise strategies to overcome common barriers to care experienced by TGD individuals. 

Chapter: Case Series: Drug Therapy for Obesity Management

• Evaluate the current guidelines for the pharmacotherapy management of obesity.
• Devise a pharmacotherapy regimen for a patient with obesity given patient-specific factors.
• Assess the safety and tolerability of a pharmacotherapy regimen.
• Justify pharmacotherapy for pediatric patients with obesity, those with monogenic disorders, older people, and patients who are pregnant and lactating.

Faculty Information

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships:

Consultancies: Jennifer D. Goldman (Sanofi; Novo Nordisk; Lilly); Diana Isaacs (Sanofi; Lifescan; Medtronic)
Stock Ownership: Kylie N. Barnes (Inovio Pharmaceuticals); Jennifer D. Goldman (Lilly; Novo Nordisk; Abbott); Alexandra Herman(Citius Pharmaceuticals; Soligenix; Zomedica)
Grants: Ha Phan (Dexcom)
Honoraria: Hailey Choi (Novo Nordisk); Jennifer D. Goldman (Novo Nordisk; Lilly; Abbott Diabetes; Bayer; Boehringer-Ingelheim; Amarin); Diana Isaacs (Novo Nordisk; Dexcom; Abbott; Lilly)

All other persons in control of content do not have any relevant financial relationships with an ineligible company. 

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

• Complete the attestation statement
• Review all content
• Complete and pass the assessments
• Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

ACCP and ASHP collaborate on ambulatory care pharmacy activities.